EMA to review safety of somatropin
This article was originally published in Scrip
The European Medicines Agency has today said that it will reassess the benefit:risk balance of medicines containing the human growth hormone somatropin. The move comes in response to a long-term study in patients treated during childhood with somatropin, which suggests that the drug carries a higher risk of mortality compared with the general population.
You may also be interested in...
Financial ties between companies and healthcare bodies distort the production and use of evidence, claims a paper co-authored by researchers, clinicians and decision makers, including a representative of Germany’s HTA body, IQWiG.
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.
Softening provisions to make EU-wide joint clinical assessments voluntary would make proposed legislation on HTA cooperation redundant, says Eurordis.